TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06797336: A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors

Sponsor: PAQ Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06797336 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06797336 Rescue Dossier →